Latest News On FDA

Latest KFF Health News Stories

In a Murky Sea of Mental Health Apps, Consumers Left Adrift

KFF Health News Original

Venture capitalists have poured billions into the digital mental health space, sensing an area of unmet demand that is ripe for disruption. The problem for consumers is separating the apps that might help from those that offer little more than distraction — or could actually do harm.

KHN’s ‘What the Health?’: The ACA Lives

KFF Health News Original

In a surprisingly strong 7-2 decision, the Supreme Court turned back the latest constitutional challenge to the Affordable Care Act, likely heralding the end of GOP efforts to strike the law in its entirety through court action. Meanwhile, Democratic lawmakers are looking for ways to expand health benefits. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Andy Slavitt, who recently stepped down from the Biden administration’s covid response team, about his new book on the pandemic.

KHN’s ‘What the Health?’: Our 200th Episode!

KFF Health News Original

The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.

FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy

KFF Health News Original

The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.

KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag

KFF Health News Original

Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.

KHN’s ‘What the Health?’: Sharing Vaccines With the World

KFF Health News Original

The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Detecting Rare Blood Clots Was a Win, But US Vaccine Safety System Still Has Gaps

KFF Health News Original

With some 100 million Americans fully vaccinated, the U.S. is relying on a patchwork network of vaccine monitoring systems that lack the breadth and depth of large, population-based programs, experts said.

Scientists Seek Covid Treatment Answers in Cheap, Older Drugs

KFF Health News Original

Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.

Analysis: How the US Invested in the War on Terrorism at the Cost of Public Health

KFF Health News Original

After 9/11, as our defenses against international and bioterrorism hardened, our defenses against infectious diseases shrank. By the time a deadly virus arrived on our shores last year, nearly two-thirds of Americans were living in counties that spend more than twice as much on policing as they spend on public health.

KHN’s ‘What the Health?’: Getting Down to Work at HHS

KFF Health News Original

After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.

Birx Joins Air-Cleaning Industry Amid Land Grab for Billions in Federal Covid Relief

KFF Health News Original

Air-cleaning companies with limited oversight are targeting a growing market of schools desperate for covid-19 protection. Donald Trump’s former covid adviser lands with one that built its business, in part, on ozone-emitting technology.

The Hype Has Faded, but Don’t Count Out Convalescent Plasma in Covid Battle

KFF Health News Original

The once-promising therapy that infuses blood plasma from recovered covid-19 patients into newly infected people, theoretically to boost immunity, has suffered setbacks. But some proponents say it’s too early to abandon the treatment.

To Extract More Doses per Vial, Vaccinators Put Squeeze on FDA to Relax Vaccine Handling Advice

KFF Health News Original

Although vaccine supply is ramping up, the supply gap puts pressure on vaccinating teams to extract every drop they can. Some are asking the FDA to waive guidance against extracting vaccine from two vials with the same needle. It’s worth a shot.